Physiological and Biochemical Analysis of Cardiovascular Complications in Type 2 Diabetes Mellitus Patients
DOI:
https://doi.org/10.52783/jns.v14.2671Keywords:
Cardiovascular disease, Diabetes type 2, Heart disease medications, Drug interactionAbstract
Numerous researchers have examined drug interactions using various living organisms, including humans and animals, to mitigate or prevent the risks associated with drug-disease interactions while enhancing drug efficacy.
This study aimed to explore the association between cardiovascular disease (CVD), particularly atherosclerotic CVD (AsCVD), in patients with type 2 diabetes (T2D) who were prescribed sodium-glucose co-transporter-2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Additionally, it sought to provide further insights into the prevalence of CVD among T2D patients. The research included 422 T2D patients diagnosed in Erbil, Kurdistan, Iraq, who were receiving care at secondary healthcare facilities. The median age of participants was 66 years, with a median diabetes duration of 13.3 years. Findings revealed that AsCVD accounted for 27.2% of all CVD cases, with coronary heart disease being the most prevalent (20.8%), followed by carotid artery disease (12.1%). Biguanides were the most commonly prescribed medication (74.2%), used in treating 75.9% of the patients. The study also indicated that CVD patients had a higher usage rate of SGLT2is and a lower usage rate of GLP-1 RAs compared to non-CVD patients, with usage rates of 16.9% and 14.5% versus 14.8% and 15.1%, respectively. The primary objective of this research was to examine the dual role of these medications, which are primarily used for T2D treatment but also exhibit beneficial pharmacological effects in patients with cardiovascular disease.
Downloads
Metrics
References
Tsao CW, Aday AW, Almarzooq ZI et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation 2022; 145: (8). doi:10.1161/CIR.0000000000001052.
Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension 2020; 75: (2)285–292.
Coronado F, Melvin SC, Bell RA et al. Global Responses to Prevent, Manage, and Control Cardiovascular Diseases. Prev Chronic Dis 2022; 19220347.
Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol 2020; 76: (25)2982–3021.
Rippe JM. Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. Am J Lifestyle Med 2019; 13: (2)204–212.
Reed J, Bain S, Kanamarlapudi V. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives. Diabetes, Metab Syndr Obes Targets Ther 2021; Volume 143567–3602.
Galicia-Garcia U, Benito-Vicente A, Jebari S et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci 2020; 21: (17)6275.
Li M, Chi X, Wang Y et al. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther 2022; 7: (1)216.
Ormazabal V, Nair S, Elfeky O et al. Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol 2018; 17: (1)122.
Artasensi A, Pedretti A, Vistoli G et al. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules 2020; 25: (8)1987.
Kyrou I, Tsigos C, Mavrogianni C et al. Sociodemographic and lifestyle-related risk factors for identifying vulnerable groups for type 2 diabetes: a narrative review with emphasis on data from Europe. BMC Endocr Disord 2020; 20: (S1)134.
De Rosa S, Arcidiacono B, Chiefari E et al. Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and Epigenetic Links. Front Endocrinol (Lausanne) 2018; 9. doi:10.3389/fendo.2018.00002.
Joseph JJ, Deedwania P, Acharya T et al. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation 2022; 145: (9). doi:10.1161/CIR.0000000000001040.
Cui J, Liu Y, Li Y et al. Type 2 Diabetes and Myocardial Infarction: Recent Clinical Evidence and Perspective. Front Cardiovasc Med 2021; 8. doi:10.3389/fcvm.2021.644189.
Jensen ES, Olesen KKW, Gyldenkerne C et al. Cardiovascular risk in patients with and without diabetes presenting with chronic coronary syndrome in 2004–2016. BMC Cardiovasc Disord 2021; 21: (1)579.
Hayfron-Benjamin C, van den Born B-J, Maitland - van der Zee AH et al. Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study. J Diabetes Complications 2019; 33: (8)572–578.
Armengol GD, Hayfron-Benjamin CF, van den Born B-JH et al. Microvascular and macrovascular complications in type 2 diabetes in a multi-ethnic population based in Amsterdam. The HELIUS study. Prim Care Diabetes 2021; 15: (3)528–534.
Ma C-X, Ma X-N, Guan C-H et al. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol 2022; 21: (1)74.
Patorno E, Htoo PT, Glynn RJ et al. Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Ann Intern Med 2021; 174: (11)1528–1541.
Marx N, Husain M, Lehrke M et al. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation 2022; 146: (24)1882–1894.
Alyousif SMM, Aldokhel FT, Alkhanbashi OK et al. The Incidence of Congenital Heart Defects in Offspring Among Women With Diabetes in Saudi Arabia. Cureus 2021. doi:10.7759/cureus.14225.
Darabi Z, Najafi F, Safari-Faramani R et al. Controlled direct effect of psychiatric disorders on cardiovascular disease: evidence from a large Kurdish cohort. BMC Cardiovasc Disord 2020; 20: (1)501.
Zhang R, Mamza JB, Morris T et al. Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals. BMC Med 2022; 20: (1)63.
Bueno Junior CR, Bano A, Tang Y et al. Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort. Cardiovasc Diabetol 2023; 22: (1)131.
Penno G, Orsi E, Solini A et al. Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: a prospective cohort study. BMJ Open Diabetes Res Care 2020; 8: (1). doi:10.1136/bmjdrc-2020-001481.
Prevalence of type 2 diabetes associated complications ion Kurdistan Region Iraq. .
Mala Ahmed N, Dauod A, Sulaiman K. Perception of cardiovascular diseases among women attending primary health care centers in Erbil city, Iraq. Zanco J Med Sci 2022; 26: (1)1–12.
Abdulah DM, Miro SS. Prevalence and correlated factors for chronic total occlusion in patients with coronary artery disease in Iraqi Kurdistan. Ann Clin Biomed Res 2022; 3: (1). doi:10.4081/acbr.2022.170.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
